Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
69.35 EUR | +1.31% | -7.31% | -12.91% |
Apr. 26 | COMPUGROUP MEDICAL : Buy rating from Baader Bank | ZD |
Apr. 25 | COMPUGROUP MEDICAL : Jefferies gives a Neutral rating | ZD |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.91% | 1.61B | - | ||
+12.25% | 325B | B- | ||
+23.70% | 214B | B+ | ||
+2.84% | 149B | B | ||
+14.15% | 58.18B | D+ | ||
+6.32% | 31.42B | B+ | ||
+6.75% | 30.71B | C+ | ||
+100.88% | 22.51B | D+ | ||
+27.94% | 20.66B | B- | ||
+0.98% | 14.85B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- COP Stock
- COP Stock
- Ratings CompuGroup Medical Societas Europaea